Sex Differences in Medication Discontinuation in Axial Spondyloarthritis
Arthritis Care & Research · 2026
DOI: 10.1002/acr.70001 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Rachael Stovall und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle. Hauptthemen laut MEDLINE: Axial Spondyloarthritis, Antirheumatic Agents, Tumor Necrosis Factor Inhibitors, Janus Kinase Inhibitors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, NIA NIH HHS, Spondylitis Association of America.
Abstract (Originalsprache)
Objective
We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi).
Methods
Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed medication discontinuation by sex among new users of TNFi, IL‐17i, and JAKi. Cox regression models were used to evaluate associations between sex and treatment discontinuation, adjusting for sociodemographic and clinical factors. We also examined medication continuation by sex and age group (18–64 vs ≥65 years) using Kaplan‐Meier curves and tested for interactions between sex and age, race, and area deprivation index (ADI).
Results
Among 7,200 individuals, the mean ± SD age was 52.7 ± 14.7 years; 58.3% were female and 68.7% were non‐Hispanic White. Among TNFi users (N = 6,256), women had a 24% higher risk of discontinuation compared to men (hazard ratio [HR]: 1.24; 95% confidence interval [CI]: 1.16–1.32). Among IL‐17i users (n = 693), women had a 25% higher risk of discontinuation (HR: 1.25; 95% CI: 1.01–1.54). No significant sex differences were observed among JAKi users (N = 251). Among TNFi users, women under 65 years had the lowest probability of treatment continuation. There was no statistically significant interaction between sex and age, race or ADI.
Conclusions
In a large US registry, women with axSpA were more likely to discontinue TNFi and IL‐17i than men. Larger studies with longer follow‐up since treatment approval are needed to confirm the lack of sex differences in JAKi discontinuation as this group could be underpowered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Washington, Seattle.
- University of California, San Francisco.
- Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
- VA Puget Sound Health Care System, Seattle, Washington.
- San Francisco VA Health Care System, San Francisco, California.
- University of California, San Francisco Institute for Health Policy Research.
ORCID-Profile: Eric Roberts, Katherine Wysham, Namrata Singh, Lianne S Gensler, Gabriela Schmajuk, Jinoos Yazdany
Förderung
- NIAMS NIH HHS
- NIA NIH HHS
- Spondylitis Association of America
- Spondyloarthritis Research and Treatment Network
- Rheumatology Research Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute on Aging
Zitieren
APA
Stovall, R., Blat, C., Roberts, E., Liew, J. W., Wysham, K., Singh, N., Friedly, J., Gensler, L. S., Schmajuk, G., & Yazdany, J. (2026). Sex Differences in Medication Discontinuation in Axial Spondyloarthritis. Arthritis Care & Research. https://doi.org/10.1002/acr.70001
Vancouver
Stovall R, Blat C, Roberts E, Liew JW, Wysham K, Singh N, et al. Sex Differences in Medication Discontinuation in Axial Spondyloarthritis. Arthritis Care & Research. 2026. doi:10.1002/acr.70001
BibTeX
@article{Stovall2026,
author = {Stovall, Rachael and Blat, Cinthia and Roberts, Eric and Liew, Jean W and Wysham, Katherine and Singh, Namrata and Friedly, Janna and Gensler, Lianne S and Schmajuk, Gabriela and Yazdany, Jinoos},
title = {Sex Differences in Medication Discontinuation in Axial Spondyloarthritis},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.70001}
}
EUVIMED